ICH M10 draft [Regulatives / Guidelines]

posted by wienui – Germany, Oman, 2019-03-13 18:06  – Posting: # 20023
Views: 869

Dear all,

"New or Alternative Technologies" an interesting part in the newly issued draft of BIOANALYTICAL METHOD VALIDATION, ICH M10 which Endorsed on 26 February 2019.

- When a new or alternative technology is used as the sole bioanalytical technology from the onset of drug development, cross-validation with an existing technology is not required.
Cross-validation but required when using two different bioanalytical technologies for the development of a drug.

on the other hand, The use of two methods or technologies within a
comparative BA/BE study is strongly discouraged:. (i.e not applicable at all also with cross-validation).:confused::confused:
Why ??

Best regards,
Osama


Edit: Post moved. [Helmut]

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,537 posts in 4,144 threads, 1,338 registered users;
online 17 (0 registered, 17 guests [including 7 identified bots]).
Forum time (Europe/Vienna): 17:17 CEST

When puzzled, it never hurts to read the primary documents –
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5